Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motixafortide in AML Consolidation
NCT02502968Phase 2Unknown
- Start
- Sep 2015
- Primary completion
- Jul 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Cytarabine & BL8040 with Cytarabine & Placebo (2 arms). Primary endpoint: Relapse Free Survival time at 18 months. Status: unknown.
02
Drugs
motixafortide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02502968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502968.